Zhan J - Search Results

1

Human epidermal growth factor receptor-2 antibodies enhance the specificity and anticancer activity of light-sensitive doxorubicin-labeled liposomes.

Li Q, Tang Q, Zhang P, Wang Z, Zhao T, Zhou J, Li H, Ding Q, Li W, Hu F, Du Y, Yuan H, Chen S, Gao J, Zhan J, You J. Li Q, et al. Among authors: zhan j. Biomaterials. 2015 Jul;57:1-11. doi: 10.1016/j.biomaterials.2015.04.009. Epub 2015 Apr 21. Biomaterials. 2015. PMID: 25956192

2

[Expression of recombinant ribosome inactivating protein MAP30 in E.coli and its biological activity].

Zhang LL, Ding Q, Zhan JB. Zhang LL, et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2010 May;39(3):264-71. doi: 10.3785/j.issn.1008-9292.2010.03.009. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2010. PMID: 20544988 Chinese.

3

[Development of therapeutic antibodies for gastric and colorectal cancers].

Zhao TT, Fan NN, Lin L, Din Q, Zhan JB. Zhao TT, et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2012 May;41(3):345-52. doi: 10.3785/j.issn.1008-9292.2012.03.019. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2012. PMID: 22723173 Review. Chinese.

4

[Antibody-drug conjugates and their application in the treatment of hematological malignancies].

Lin L, Ding Q, Tang Q, Zhang ZZ, Dai Z, Zhan JB. Lin L, et al. Yao Xue Xue Bao. 2012 Oct;47(10):1287-96. Yao Xue Xue Bao. 2012. PMID: 23289140 Review. Chinese.

5

[Development of antibody drugs targeting against HER2 for cancer therapy].

Tang Q, Ding Q, Lin L, Zhang ZZ, Dai Z, Zhan JB. Tang Q, et al. Yao Xue Xue Bao. 2012 Oct;47(10):1297-305. Yao Xue Xue Bao. 2012. PMID: 23289141 Review. Chinese.

6

Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer.

Ding Q, Zhan J. Ding Q, et al. Among authors: zhan j. Drug Des Devel Ther. 2013 Aug 1;7:681-9. doi: 10.2147/DDDT.S41910. eCollection 2013. Drug Des Devel Ther. 2013. PMID: 23946645 Free PMC article. Review.

7

Construction of high level prokaryotic expression and purification system of PD-L1 extracellular domain by using Escherichia coli host cell machinery.

Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, Ding Q, Chen S, Zhan J. Kalim M, et al. Among authors: zhan j. Immunol Lett. 2017 Oct;190:34-41. doi: 10.1016/j.imlet.2017.06.004. Epub 2017 Jul 3. Immunol Lett. 2017. PMID: 28684274

8

Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.

Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, Ding Q, Chen S, Zhan J. Kalim M, et al. Among authors: zhan j. Drug Des Devel Ther. 2017 Aug 2;11:2265-2276. doi: 10.2147/DDDT.S135571. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28814834 Free PMC article. Review.

9

Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells.

Liang K, Mei S, Gao X, Peng S, Zhan J. Liang K, et al. Among authors: zhan j. Drug Des Devel Ther. 2021 Dec 24;15:5135-5150. doi: 10.2147/DDDT.S344052. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34992350 Free PMC article.

10

Development of antibody therapeutics for small cell lung cancer.

Zhan J, Han Q, Wang K. Zhan J, et al. Expert Opin Investig Drugs. 2013 Feb;22(2):235-44. doi: 10.1517/13543784.2013.750293. Epub 2012 Nov 24. Expert Opin Investig Drugs. 2013. PMID: 23176362 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,697 results

Search Page

Filters